• This article examines whether Viking Therapeutics at US$30.89 is pricing in too much optimism or still offers potential value, by exploring what the current share price might be indicating.
• The stock is up 7.7% over the past week, while it is down 5.7% over the past month and down 12.8% year to date. It still shows a 14.5% return over the past year and a very large gain over five years.
• Recent trading has been influenced by ongoing interest in Viking Therapeutics within the biotech space, where investors often react strongly to clinical or regulatory headlines even when there is no immediate change to fundamentals. This context helps explain why short-term moves can look very different from the longer-term return profile.
• Right now Viking Therapeutics has a valuation score of 2 out of 6. The next sections explain how traditional valuation checks lead to that score, then introduce a framework that can help you assess the stock's value in a more complete way.

Viking Therapeutics scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Viking Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and discounting them back to today using a required return. It is essentially asking what those future cash flows are worth in present day dollars.

For Viking Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The company currently reports free cash flow of a loss of $340.33 million. Analyst and extrapolated estimates suggest free cash flow remains in loss territory for several years, with projections such as $601.291 million and $585.729 million of free cash flow losses in 2026 and 2028, before moving to a projected free cash flow of $148.145 million in 2030. Further projections beyond analyst estimates are extrapolated by Simply Wall St.

Bringing all those projected cash flows back to today results in an estimated intrinsic value of about $44.22 per share. Compared with the recent share price of $30.89, the DCF output suggests the stock is trading at about a 30.1% discount. On this model alone, that indicates an undervalued reading.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Viking Therapeutics is undervalued by 30.1%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

Approach 2: Viking Therapeutics Price vs Book

For companies that are not yet generating consistent profits, price based multiples linked to the balance sheet can be more useful than earnings based measures. Price to book, or P/B, compares the market value of the equity to its accounting net assets, which is often a reference point for early stage biotechs.

Growth expectations and risk still matter here. Investors usually accept a higher P/B ratio if they see stronger growth potential and are comfortable with the risks, while slower growth or higher risk tends to justify a lower multiple.

Viking Therapeutics currently trades on a P/B ratio of 7.15x, compared with the Biotechs industry average of about 2.50x and a peer average of 5.50x. Simply Wall St also uses a proprietary “Fair Ratio” for P/B, which represents the multiple suggested by factors such as earnings growth trends, industry, profit margin, market cap and company specific risks. This is designed to be more tailored than a simple comparison with peers or the wider industry, because it adjusts the benchmark for the company’s own profile.

On this framework, Viking Therapeutics’ actual 7.15x P/B is higher than its Fair Ratio, which points to the stock looking overvalued on a price to book basis.

Result: OVERVALUED

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Viking Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, a simple way for you to write the story behind your numbers by linking your views on Viking Therapeutics’ future revenue, earnings and margins to a financial forecast, a Fair Value and a clear comparison with the current price. This is all available inside the Simply Wall St Community page that millions of investors use. Narratives update automatically when new earnings or news arrive so you can see, for example, how one investor might build a bullish story around a Fair Value of US$125 while another anchors on a more cautious US$35, and then decide for yourself where your own view fits on that spectrum.

Do you think there's more to the story for Viking Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.